Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
1. A method for the treatment and/or prevention of pain, the method comprising administering to a subject in need thereof a therapeutically effective amount of 1-(3-(4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), wherein the AV1066 is in the (−) form substantially absent the (+) form.
2. The method of claim 1 , comprising administering the AV1066 in a dosage of from about 5 mg/kg/day to about 50 mg/kg/day.
3. The method of claim 2 , wherein the dosage is from about 10 mg/kg/day to about 30 mg/kg/day.
4. The method of claim 1 , comprising administering the AV1066 in a dosage of from about 250 mg/day to about 1000 mg/day.
5. The method of claim 4 , wherein the dosage is from about 350 mg/day to about 750 mg/day.
6. The method of claim 1 , wherein the pain is nociceptive pain.
7. The method of claim 2 , wherein the pain is visceral pain and the method comprises administering AV1066 in a dosage of from about 5 mg/kg/day to about 50 mg/kg/day.
8. The method of claim 7 , wherein the dosage is from about 10 mg/kg/day to about 30 mg/kg/day.
9. The method of claim 1 , wherein the pain is visceral pain and the method comprises administering AV1066 in a dosage of from about 250 mg/day to about 1000 mg/day.
10. The method of claim 9 , wherein the dosage is from about 350 mg/day to about 750 mg/day.
11. The method of claim 1 , wherein the pain is neuropathic pain and the method comprises administering AV1066 in a dosage of from about 5 mg/kg/day to about 50 mg/kg/day.
12. The method of claim 11 , wherein the dosage is from about 10 mg/kg/day to about 30 mg/kg/day.
13. The method of claim 1 , wherein the pain is neuropathic pain and the method comprises administering AV1066 in a dosage of from about 250 mg/day to about 1000 mg/day.
14. The method of claim 13 , wherein the dosage is from about 350 mg/day to about 750 mg/day.
15. The method of claim 1 , wherein the pain is hyperalgesia pain and the method comprises administering AV1066 in a dosage of from about 5 mg/kg/day to about 50 mg/kg/day.
16. The method of claim 15 , wherein the dosage is from about 10 mg/kg/day to about 30 mg/kg/day.
17. The method of claim 1 , wherein the pain is hyperalgesia pain and the method comprises administering AV1066 in a dosage of from about 250 mg/day to about 1000 mg/day.
18. The method of claim 17 , wherein the dosage is from about 350 mg/day to about 750 mg/day.
19. The method of claim 1 , wherein the AV1066 is in the sodium salt form.
20. The method of claim 1 , wherein the AV1066 is in the phosphate salt form.
21. The method of claim 1 , wherein the administration of the AV1066 comprises administering the AV1066 with a pharmaceutically acceptable carrier.